# Clinical trial results:
# Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis

## Summary

| | |
|---|---|
| EudraCT number | 2010-023669-23 |
| Trial protocol | AT IT CZ GR ES HU SK |
| Global end of trial date | 30 May 2014 |

**Results information**

| | |
|---|---|
| Result version number | v2 (current) |
| This version publication date | 23 June 2016 |
| First version publication date | 02 August 2015 |
| Version creation reason | • Correction of full data set<br>Review of data |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | VX-950HEP3002 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01508286 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | Janssen-Cilag International NV |
| Sponsor organisation address | Antwerpseweg 15-17, Beerse, Belgium, B-2340 |
| Public contact | Janssen-Cilag International NV - Clinical Registry Group, Janssen Biologics BV, ClinicalTrialsEU@its.jnj.com |
| Scientific contact | Janssen-Cilag International NV - Clinical Registry Group, Janssen Biologics BV, ClinicalTrialsEU@its.jnj.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 30 May 2014 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 30 May 2014 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this early access program was to provide telaprevir for participants with genotype 1 chronic hepatitis C with severe fibrosis or compensated cirrhosis who resided in countries in which telaprevir was not commercially available at the time of protocol writing and who were not eligible for enrollment into an ongoing clinical study of telaprevir, and to collect additional safety and tolerability data on telaprevir treatment in combination with pegylated interferon alpha (Peg-IFN-alfa) and ribavirin (RBV).

Protection of trial subjects:

Assessment of safety and tolerability was based on reported adverse events (AEs), clinical laboratory tests, vital sign measurements, electrocardiogram (ECG) monitoring, and physical examinations.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 24 May 2011 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Australia: 60 |
| Country: Number of subjects enrolled | Austria: 23 |
| Country: Number of subjects enrolled | Belgium: 53 |
| Country: Number of subjects enrolled | Brazil: 97 |
| Country: Number of subjects enrolled | Switzerland: 17 |
| Country: Number of subjects enrolled | Czech Republic: 45 |
| Country: Number of subjects enrolled | Germany: 95 |
| Country: Number of subjects enrolled | Greece: 29 |
| Country: Number of subjects enrolled | Spain: 160 |
| Country: Number of subjects enrolled | Hungary: 134 |
| Country: Number of subjects enrolled | Italy: 568 |
| Country: Number of subjects enrolled | Luxembourg: 4 |
| Country: Number of subjects enrolled | New Zealand: 21 |
| Country: Number of subjects enrolled | Romania: 218 |
| Country: Number of subjects enrolled | Russian Federation: 185 |
| Country: Number of subjects enrolled | Serbia: 63 |
| Worldwide total number of subjects | 1772 |
| EEA total number of subjects | 1329 |

Notes:

| Subjects enrolled per age group | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 1585 |
| From 65 to 84 years | 187 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 2034 participants were screened for this early access program. Of these, 1772 participants were treated with telaprevir. 1587 participants completed the early access program.

### Period 1

| | |
|---|---|
| Period 1 title | Overall (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| **Arm title** | Telaprevir + Pegylated Interferon/Ribavirin |

Arm description:

Participants received Telaprevir 750 milligram (mg) (2*375 mg) tablet orally every 8 hours for the first 12 weeks of the early access program in combination with Pegylated Interferon/Ribavirin followed by 12 or 36 weeks of treatment with Pegylated Interferon/Ribavirin alone.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Telaprevir |
| Investigational medicinal product code | VX-950 |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants were received Telaprevir 750 (2*375) milligram (mg) tablet orally every 8 hours for first 12 weeks of the early access program in combination with Pegylated Interferon/Ribavirin.

| **Number of subjects in period 1** | Telaprevir + Pegylated Interferon/Ribavirin |
|---|---|
| Started | 1772 |
| Completed | 1587 |
| Not completed | 185 |
| Adverse event, serious fatal | 9 |
| Consent withdrawn by subject | 75 |
| Adverse event, non-fatal | 2 |
| Other | 7 |
| Participant entered another investigational trial | 2 |
| Lost to follow-up | 90 |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Telaprevir + Pegylated Interferon/Ribavirin |
| Reporting group description: | |
| Participants received Telaprevir 750 milligram (mg) (2*375 mg) tablet orally every 8 hours for the first 12 weeks of the early access program in combination with Pegylated Interferon/Ribavirin followed by 12 or 36 weeks of treatment with Pegylated Interferon/Ribavirin alone. | |

| Reporting group values | Telaprevir + Pegylated Interferon/Ribavirin | Total | |
|---|---|---|---|
| Number of subjects | 1772 | 1772 | |
| Title for AgeCategorical<br>Units: subjects | | | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 1585 | 1585 | |
| From 65 to 84 years | 187 | 187 | |
| 85 years and over | 0 | 0 | |
| Title for AgeContinuous<br>Units: years | | | |
| arithmetic mean | 53 | | |
| standard deviation | ± 9.49 | - | |
| Title for Gender<br>Units: subjects | | | |
| Female | 651 | 651 | |
| Male | 1121 | 1121 | |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Telaprevir + Pegylated Interferon/Ribavirin |

Reporting group description:

Participants received Telaprevir 750 milligram (mg) (2*375 mg) tablet orally every 8 hours for the first 12 weeks of the early access program in combination with Pegylated Interferon/Ribavirin followed by 12 or 36 weeks of treatment with Pegylated Interferon/Ribavirin alone.

| | |
|---|---|
| Subject analysis set title | Treatment naive |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Participants who had never received hepatitis C virus (HCV) drugs.

| | |
|---|---|
| Subject analysis set title | Prior relapser |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Participants with confirmed detectable hepatitis C virus (HCV) ribonucleic acid (RNA) during the follow-up period after previous HCV RNA 'less than (<) lower limit of quantification (LLOQ), target not detected' at the end of treatment.

| | |
|---|---|
| Subject analysis set title | Prior null responder |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Participants who had a < 2-log10 decrease in HCV RNA level at Week 12 compared to baseline HCV RNA level during prior treatment.

| | |
|---|---|
| Subject analysis set title | Prior partial responder |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Participants who had a greater than or equal to (>=) 2-log10 decrease in HCV RNA level at Week 12 compared to baseline HCV RNA level, but never had HCV RNA '<LLOQ, target not detected' during prior treatment.

| | |
|---|---|
| Subject analysis set title | Prior non-responder |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Participants who never had HCV RNA '<LLOQ, target not detected' during prior treatment. This includes prior null responder and prior partial responder.

| | |
|---|---|
| Subject analysis set title | Viral breakthroughs |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

A confirmed increase greater than (>) 1 log10 in HCV RNA level from the lowest level reached during the considered treatment phase up to the considered time point, if the lowest level reached was >LLOQ, or a confirmed value of HCV RNA >100 International units per milliliter (IU/mL) in participants whose HCV RNA had previously become <LLOQ ('target detected' or 'target not detected') during the considered treatment phase.

### Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR) 24actual (Snapshot, less than [<] lower limit of quantification [LLOQ]) 24 Weeks After the Last Actual Dose of Hepatitis C Virus (HCV) Drug

| | |
|---|---|
| End point title | Percentage of Participants Achieving Sustained Virologic Response (SVR) 24actual (Snapshot, less than [<] lower limit of quantification [LLOQ]) 24 Weeks After the Last Actual Dose of Hepatitis C Virus (HCV) Drug[1] |

End point description:

The SVR24actual (Snapshot, <LLOQ), defined as achieving HCV RNA <LLOQ at the last nonmissing measurement in the Week 24 Follow-up visit window (that is, date from last intake of HCV drug [telaprevir, Peg-IFN-alfa, or RBV] +71 days until date of last contact).

| | |
|---|---|
| End point type | Primary |

End point timeframe:

Week 72

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed

| **End point values** | Treatment naive | Prior relapser | Prior null responder | Prior partial responder |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 355 | 586 | 495 | 234 |
| Units: Percentage | | | | |
| number (not applicable) | 73.8 | 78.2 | 44 | 60.3 |

| **End point values** | Prior non-responder | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 830 | | | |
| Units: Percentage | | | | |
| number (not applicable) | 50.5 | | | |

**Statistical analyses**

No statistical analyses for this end point

## Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR) 24actual (Snapshot, 'less than [<] lower limit of quantification [LLOQ], target not detected') 24 Weeks After the Last Actual Dose of Hepatitis C Virus (HCV) Drug

| End point title | Percentage of Participants Achieving Sustained Virologic Response (SVR) 24actual (Snapshot, 'less than [<] lower limit of quantification [LLOQ], target not detected') 24 Weeks After the Last Actual Dose of Hepatitis C Virus (HCV) Drug[2] |
|---|---|

End point description:

The SVR24actual (Snapshot, '<LLOQ, target not detected'), defined as achieving HCV RNA '<LLOQ, target not detected' at the last nonmissing measurement in the Week 24 Follow-up visit window.

| End point type | Primary |
|---|---|

End point timeframe:

Week 72

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed

| **End point values** | Treatment naive | Prior relapser | Prior null responder | Prior partial responder |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 355 | 586 | 495 | 234 |
| Units: Percentage | | | | |
| number (not applicable) | 73.5 | 77.6 | 43.8 | 60.3 |

| End point values | Prior non-responder | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 830 | | | |
| Units: Percentage | | | | |
| number (not applicable) | 50.2 | | | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR) 24actual (Classic) 24 Weeks After the Last Actual Dose of Hepatitis C Virus (HCV) Drug

| End point title | Percentage of Participants Achieving Sustained Virologic Response (SVR) 24actual (Classic) 24 Weeks After the Last Actual Dose of Hepatitis C Virus (HCV) Drug[3] |
|---|---|

End point description:

The SVR24actual (Classic), defined as having HCV RNA '<LLOQ, target not detected' at End of Treament, and having at least one nonmissing HCV RNA measurement in the Week 24 Follow-up visit window, and not having relapsed, and having completed treatment (all HCV drugs) or having permanently discontinued at least one of the HCV drugs but for a reason other than virologic failure.

| End point type | Primary |
|---|---|

End point timeframe:

Week 72

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed

| End point values | Treatment naive | Prior relapser | Prior null responder | Prior partial responder |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 317 | 538 | 427 | 214 |
| Units: Percentage | | | | |
| number (not applicable) | 79.5 | 83.8 | 50.1 | 64.5 |

| End point values | Prior non-responder | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 733 | | | |
| Units: Percentage | | | | |
| number (not applicable) | 55.8 | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at Each Time Point During Treatment

| End point title | Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at Each Time Point During Treatment[4] |
|---|---|

End point description:

Change from baseline in log10 of Plasma Hepatitis C Virus (HCV) ribonucleic acid (RNA) levels were measured using HCV test (lower limit of quantification 25 international units/milliliter [IU/mL]). The assay used real-time reverse transcription - polymerase chain reaction (RT-PCR) methodology. HCV RNA samples were taken pre-dose of Pegylated-interferon (Peg-IFN) administration.

| End point type | Primary |
|---|---|

End point timeframe:

Baseline and Week 4

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed

| **End point values** | Treatment naive | Prior relapser | Prior non-responder | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 355 | 586 | 830 | |
| Units: International unit per milliliter(IU/ml) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline (n= 355, 586, 830) | 6 (± 0.76) | 6.1 (± 0.72) | 6.2 (± 0.66) | |
| Change at Week 4 (n= 329, 586, 830) | -5.04 (± 0.892) | -5.1 (± 0.812) | -4.96 (± 1.018) | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4

| End point title | Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4[5] |
|---|---|

End point description:

Percentage of participants who had a Rapid Virologic Response (RVR) (that is, those with undetectable hepatitis C virus [HCV] ribonucleic acid [RNA] values of less than 25 international units/milliliter [IU/mL], target not detected at Weeks 4 of treatment) were evaluated.

| End point type | Primary |
|---|---|

End point timeframe:

Week 4

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed

| End point values | Treatment naive | Prior relapser | Prior non-responder | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 355 | 586 | 830 | |
| Units: Percentage | | | | |
| number (not applicable) | 63.9 | 69.6 | 50.7 | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants Achieving Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12

| End point title | Percentage of Participants Achieving Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12[6] |
|---|---|

End point description:

Percentage of participants who had a Extended Rapid Virologic Response (eRVR) (that is, those with undetectable hepatitis C virus [HCV] ribonucleic acid [RNA] values of less than 25 international units/milliliter [IU/mL], target not detected at Weeks 4 and 12 of treatment) were evaluated.

| End point type | Primary |
|---|---|

End point timeframe:

Week 4 and 12

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed

| End point values | Treatment naive | Prior relapser | Prior non-responder | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 355 | 586 | 830 | |
| Units: Percentage | | | | |
| number (not applicable) | 59.2 | 65.4 | 45.8 | |

### Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants Having Virologic Response at End of Treatment (Week 24 or 48)

| End point title | Percentage of Participants Having Virologic Response at End of Treatment (Week 24 or 48)[7] |
|---|---|

End point description:

Virologic response was either defined as having undetectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) (that is, no HCV RNA was detected in the participants' plasma samples) or less than 25 international units/milliliter (IU/mL) HCV RNA (that is, the participants' plasma samples contained traces of HCV RNA at a concentration below the limit of quantification of the viral load assay or no HCV RNA was detected in the samples).

| End point type | Primary |
|---|---|

End point timeframe:

Week 24 or 48

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed

| **End point values** | Treatment naive | Prior relapser | Prior null responder | Prior partial responder |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 355 | 586 | 495 | 234 |
| Units: Percentage | | | | |
| number (not applicable) | | | | |
| Viral Response ('<LLOQ, target not detected') | 79.4 | 84.8 | 54.7 | 75.2 |
| Viral Response (<LLOQ) | 81.7 | 85.7 | 58.2 | 78.2 |

| **End point values** | Prior non-responder | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 830 | | | |
| Units: Percentage | | | | |
| number (not applicable) | | | | |
| Viral Response ('<LLOQ, target not detected') | 62.3 | | | |
| Viral Response (<LLOQ) | 65.4 | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants With Viral Breakthrough

| End point title | Percentage of Participants With Viral Breakthrough[8] |
|---|---|

End point description:

A confirmed increase >1 log10 in HCV RNA level from the lowest level reached during the considered treatment phase up to the considered time point, if the lowest level reached was >LLOQ, or a confirmed value of HCV RNA >100 IU/mL in participants whose HCV RNA had previously become <LLOQ (detectable or 'target not detected') during the considered treatment phase.

| End point type | Primary |
|---|---|

End point timeframe:

Up to Week 48

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed

| End point values | Treatment naive | Prior relapser | Prior null responder | Prior partial responder |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 355 | 586 | 495 | 234 |
| Units: Percentage | | | | |
| number (not applicable) | | | | |
| Week 4 | 0 | 0.2 | 0.2 | 0 |
| Week 8 | 0 | 0 | 2.6 | 0.4 |
| Week 12 | 2 | 1.2 | 7.5 | 2.6 |
| Week 24 | 5.9 | 4.1 | 18.8 | 7.7 |
| Week 48 | 7.9 | 4.8 | 24.6 | 11.5 |

| End point values | Prior non-responder | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 830 | | | |
| Units: Percentage | | | | |
| number (not applicable) | | | | |
| Week 4 | 0.1 | | | |
| Week 8 | 1.8 | | | |
| Week 12 | 5.5 | | | |
| Week 24 | 14.6 | | | |
| Week 48 | 19.3 | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants who Relapsed

| End point title | Percentage of Participants who Relapsed[9] |
|---|---|

End point description:

Relapse (<LLOQ), defined as having HCV RNA <LLOQ at EOT and HCV RNA detectable during the follow-up phase, and not achieving SVR24actual (Snapshot, <LLOQ); or Relapse (‘<LLOQ, target not detected’), defined similarly with the ‘<LLOQ, target not detected’ threshold.

| End point type | Primary |
|---|---|

End point timeframe:

Week 72

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed

| End point values | Treatment naive | Prior relapser | Prior null responder | Prior partial responder |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 355 | 586 | 495 | 234 |
| Units: Percentage | | | | |
| number (not applicable) | | | | |
| 25 -< 2000 IU/mL (n = 290, 502, 288, 183, 543) | 0.7 | 0.8 | 1 | 1.1 |
| >= 2000 IU/mL (n = 290, 502, 288, 183, 543) | 8.3 | 7.6 | 21.5 | 20.2 |
| Qualitative Detectable(n =290, 502, 288, 183, 543) | 0.7 | 0.4 | 1.4 | 0.5 |

| End point values | Prior non-responder | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 830 | | | |
| Units: Percentage | | | | |
| number (not applicable) | | | | |
| 25 -< 2000 IU/mL (n = 290, 502, 288, 183, 543) | 1.1 | | | |
| >= 2000 IU/mL (n = 290, 502, 288, 183, 543) | 20.3 | | | |
| Qualitative Detectable(n =290, 502, 288, 183, 543) | 1.1 | | | |

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Participants who met a Virologic Stopping Rule

| End point title | Percentage of Participants who met a Virologic Stopping Rule[10] |
|---|---|

End point description:

Stopping rules based on virologic response at Weeks 4 and 12 were to be applied to ensure that telaprevir or Peg-IFN-alfa/RBV treatments were stopped if a participant had viral breakthrough or failure.

| End point type | Primary |
|---|---|

End point timeframe:

Week 4 and 12

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Descriptive statistics were done, no inferential statistical analyses were performed

| End point values | Treatment naive | Prior relapser | Prior null responder | Prior partial responder |
|---|---|---|---|---|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 355 | 586 | 495 | 234 |
| Units: Participants | | | | |
| number (not applicable) | | | | |
| Telaprevir stopping rule – Week 4 | 2 | 0.5 | 5.5 | 1.3 |
| RBV/Peg-IFN stopping rule – Week 12 | 2.3 | 0.7 | 5.9 | 1.3 |

| End point values | Prior non-responder | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 830 | | | |
| Units: Participants | | | | |
| number (not applicable) | | | | |
| Telaprevir stopping rule – Week 4 | 4.1 | | | |
| RBV/Peg-IFN stopping rule – Week 12 | 4 | | | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

| Adverse events information | |
|---|---|
| Timeframe for reporting adverse events: | |
| Up to Week 72 | |
| Assessment type | Non-systematic |
| **Dictionary used** | |
| Dictionary name | MedDRA |
| Dictionary version | 11.0 |
| **Reporting groups** | |
| Reporting group title | Telaprevir + Pegylated Interferon/Ribavirin |
| Reporting group description: | |
| Participants received Telaprevir 750 milligram (mg) (2*375 mg) tablet orally every 8 hours for the first 12 weeks of the early access program in combination with Pegylated Interferon/Ribavirin. | |

| Serious adverse events | Telaprevir + Pegylated Interferon/Ribavirin | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 147 / 1772 (8.30%) | | |
| number of deaths (all causes) | 2 | | |
| number of deaths resulting from adverse events | | | |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Face Oedema | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Asthenia | | | |
| subjects affected / exposed | 3 / 1772 (0.17%) | | |
| occurrences causally related to treatment / all | 3 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Influenza Like Illness | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Fatigue | | | |
| subjects affected / exposed | 3 / 1772 (0.17%) | | |
| occurrences causally related to treatment / all | 3 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Malaise | | | |
| subjects affected / exposed | 2 / 1772 (0.11%) | | |
| occurrences causally related to treatment / all | 2 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Multi-Organ Failure | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 1 / 1 | | |
| Non-Cardiac Chest Pain | | | |
| subjects affected / exposed | 2 / 1772 (0.11%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyrexia | | | |
| subjects affected / exposed | 9 / 1772 (0.51%) | | |
| occurrences causally related to treatment / all | 4 / 9 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pain | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Reproductive system and breast disorders | | | |
| Testicular Mass | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |

| | | | | |
|---|---|---|---|---|
| Dyspnoea | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cough | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Interstitial Lung Disease | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Psychiatric disorders | | | | |
| Confusional State | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Investigations | | | | |
| Alanine Aminotransferase Increased | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Haemoglobin Decreased | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 2 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Transaminases Increased | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Weight Decreased | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | |
|---|---|---|---|
| Injury, poisoning and procedural complications | | | |
| Fall | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal Injury | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Atrial Fibrillation | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Coronary Artery Disease | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac Failure | | | |
| subjects affected / exposed | 2 / 1772 (0.11%) | | |
| occurrences causally related to treatment / all | 2 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Palpitations | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Coma | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Dizziness | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 2 / 1772 (0.11%) | | | |
| occurrences causally related to treatment / all | 2 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hepatic Encephalopathy | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Encephalopathy | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Blood and lymphatic system disorders | | | | |
| Anaemia | | | | |
| alternative assessment type: Systematic | | | | |
| subjects affected / exposed | 73 / 1772 (4.12%) | | | |
| occurrences causally related to treatment / all | 73 / 73 | | | |
| deaths causally related to treatment / all | 1 / 1 | | | |
| Bone Marrow Failure | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 1 | | | |
| Leukopenia | | | | |
| subjects affected / exposed | 3 / 1772 (0.17%) | | | |
| occurrences causally related to treatment / all | 1 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lymphopenia | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Neutropenia | | | | |
| subjects affected / exposed | 5 / 1772 (0.28%) | | | |
| occurrences causally related to treatment / all | 3 / 6 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | | |
|---|---|---|---|---|
| Neutrophilia | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thrombocytopenia | | | | |
| subjects affected / exposed | 4 / 1772 (0.23%) | | | |
| occurrences causally related to treatment / all | 2 / 4 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancytopenia | | | | |
| subjects affected / exposed | 2 / 1772 (0.11%) | | | |
| occurrences causally related to treatment / all | 2 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Eye disorders | | | | |
| Retinal Disorder | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Retinal Haemorrhage | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal disorders | | | | |
| Abdominal Pain | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 2 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Anal Fissure | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 2 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ascites | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | | |
|---|---|---|---|---|
| Erosive Duodenitis | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastritis | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal Haemorrhage | | | | |
| subjects affected / exposed | 2 / 1772 (0.11%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Haemorrhoidal Haemorrhage | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nausea | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intestinal Obstruction | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatitis | | | | |
| subjects affected / exposed | 3 / 1772 (0.17%) | | | |
| occurrences causally related to treatment / all | 1 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rectal Haemorrhage | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Vomiting | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| Hepatic Cirrhosis | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bile Duct Stone | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatic Failure | | | |
| subjects affected / exposed | 2 / 1772 (0.11%) | | |
| occurrences causally related to treatment / all | 2 / 2 | | |
| deaths causally related to treatment / all | 1 / 1 | | |
| Hepatorenal Syndrome | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 1 / 1 | | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Drug Rash with Eosinophilia and Systemic Symptoms | | | |
| subjects affected / exposed | 3 / 1772 (0.17%) | | |
| occurrences causally related to treatment / all | 3 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Eczema | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | | |
|---|---|---|---|---|
| Erythema | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pruritus | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Purpura | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rash | | | | |
| subjects affected / exposed | 16 / 1772 (0.90%) | | | |
| occurrences causally related to treatment / all | 16 / 16 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rash Generalised | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rash Papular | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Toxic Skin Eruption | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal and urinary disorders | | | | |
| Renal Failure | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 1 / 1 | | | |
| Renal Failure Acute | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Endocrine disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Back Pain | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Arthritis | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bone Pain | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Bronchitis | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchopneumonia | | | |
| subjects affected / exposed | 2 / 1772 (0.11%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|---|---|---|---|
| Febrile Infection | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diarrhoea Infectious | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intervertebral Discitis | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Oral Candidiasis | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia | | | |
| subjects affected / exposed | 2 / 1772 (0.11%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psoas Abscess | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyelonephritis Acute | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyelonephritis | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sepsis | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 2 / 1772 (0.11%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Tuberculosis | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Skin Infection | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Urinary Tract Infection | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metabolism and nutrition disorders | | | | |
| Anorexia | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Dehydration | | | | |
| subjects affected / exposed | 2 / 1772 (0.11%) | | | |
| occurrences causally related to treatment / all | 2 / 2 | | | |
| deaths causally related to treatment / all | 1 / 1 | | | |
| Hypercatabolism | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 1 / 1 | | | |
| Diabetic Ketoacidosis | | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hyperglycaemia | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 1772 (0.11%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 1 / 1 | | |
| Hyperuricaemia | | | |
| subjects affected / exposed | 2 / 1772 (0.11%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hyponatraemia | | | |
| subjects affected / exposed | 3 / 1772 (0.17%) | | |
| occurrences causally related to treatment / all | 2 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ketoacidosis | | | |
| subjects affected / exposed | 1 / 1772 (0.06%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 1 / 1 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Telaprevir + Pegylated Interferon/Ribavirin | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 1293 / 1772 (72.97%) | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 933 / 1772 (52.65%) | | |
| occurrences (all) | 1435 | | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 126 / 1772 (7.11%) | | |
| occurrences (all) | 170 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 151 / 1772 (8.52%) | | |
| occurrences (all) | 172 | | |
| Gastrointestinal disorders | | | |

| | | | |
|---|---|---|---|
| Anal Pruritus | | | |
| subjects affected / exposed | 100 / 1772 (5.64%) | | |
| occurrences (all) | 101 | | |
| Nausea | | | |
| subjects affected / exposed | 146 / 1772 (8.24%) | | |
| occurrences (all) | 154 | | |
| Skin and subcutaneous tissue disorders | | | |
| Pruritus | | | |
| subjects affected / exposed | 266 / 1772 (15.01%) | | |
| occurrences (all) | 282 | | |
| Rash | | | |
| subjects affected / exposed | 424 / 1772 (23.93%) | | |
| occurrences (all) | 500 | | |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 17 May 2011 | The overall reason for the amendment was to change in collection period for serious adverse events (SAEs) and reporting period for pregnancies and the fact that female participants should discontinue treatment if they become pregnant. |
| 16 August 2011 | The overall reason for the amendment was to add the collection of an optional blood sample for genotype evaluations of specific genetic markers related to treatment response outcomes and specified adverse events including rash. |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported